Central adiposity and risk of Barrett's esophagus
- PMID: 17681161
- DOI: 10.1053/j.gastro.2007.05.026
Central adiposity and risk of Barrett's esophagus
Abstract
Background and aims: Aside from chronic reflux, the etiology of Barrett's esophagus (BE) remains largely unknown. This case-control study investigated body mass index (BMI), central adiposity, and cigarette smoking and risk of BE.
Methods: Washington residents newly diagnosed with specialized intestinal metaplasia on at least 1 of 4 esophageal biopsy specimens taken at community gastroenterology clinics (cases [n = 193]) were compared with matched population controls (n = 211). Case subgroups included those with any visible columnar epithelium (visible BE) and those with at least 2 cm of columnar epithelium (long-segment BE [LSBE]). Interviewers conducted personal interviews and took anthropometric measurements.
Results: All measures of central adiposity were strongly related to BE risk, particularly for LSBE. For the high category of waist-to-hip ratio (WHR), the adjusted odds ratios were 2.4 (95% confidence interval [CI]: 1.4-3.9) for all cases, 2.8 (95% CI: 1.5-5.1) for visible BE, and 4.3 (95% CI: 1.9-9.9) for LSBE. In contrast, the associations with BMI were weaker. When BMI and WHR were modeled simultaneously, the associations with BMI were greatly attenuated, whereas those with WHR remained strong. Further adjustment for frequency of heartburn did not change these results. Cigarette smoking moderately increased risk but with no evidence of a dose-dependent response or increasing strength by case group.
Conclusions: These observations indicate the importance of identifying the mechanisms underlying obesity's role in BE and esophageal adenocarcinoma, and suggest that weight loss might be a fruitful approach to the prevention of these diseases.
Similar articles
-
Abdominal obesity and body mass index as risk factors for Barrett's esophagus.Gastroenterology. 2007 Jul;133(1):34-41; quiz 311. doi: 10.1053/j.gastro.2007.04.046. Epub 2007 Apr 25. Gastroenterology. 2007. PMID: 17631128
-
Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12163328
-
Current and past smoking significantly increase risk for Barrett's esophagus.Clin Gastroenterol Hepatol. 2009 Aug;7(8):840-8. doi: 10.1016/j.cgh.2009.04.018. Epub 2009 May 4. Clin Gastroenterol Hepatol. 2009. PMID: 19410015
-
Role of obesity in Barrett's esophagus and cancer.Surg Oncol Clin N Am. 2009 Jul;18(3):439-52. doi: 10.1016/j.soc.2009.03.010. Surg Oncol Clin N Am. 2009. PMID: 19500735 Review.
-
Visceral obesity and the risk of Barrett's esophagus.Digestion. 2011;83(3):142-5. doi: 10.1159/000321810. Epub 2011 Jan 21. Digestion. 2011. PMID: 21266807 Review.
Cited by
-
Management of Barrett's oesophagus and intramucosal oesophageal cancer: a review of recent development.Therap Adv Gastroenterol. 2012 Sep;5(5):285-99. doi: 10.1177/1756283X12446668. Therap Adv Gastroenterol. 2012. PMID: 22973415 Free PMC article.
-
Association of Barrett's esophagus with type II Diabetes Mellitus: results from a large population-based case-control study.Clin Gastroenterol Hepatol. 2013 Sep;11(9):1108-1114.e5. doi: 10.1016/j.cgh.2013.03.024. Epub 2013 Apr 13. Clin Gastroenterol Hepatol. 2013. PMID: 23591277 Free PMC article.
-
Exercise and the Prevention of Oesophageal Cancer (EPOC) study protocol: a randomized controlled trial of exercise versus stretching in males with Barrett's oesophagus.BMC Cancer. 2010 Jun 16;10:292. doi: 10.1186/1471-2407-10-292. BMC Cancer. 2010. PMID: 20550712 Free PMC article. Clinical Trial.
-
Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction.Obesity (Silver Spring). 2010 Nov;18(11):2204-11. doi: 10.1038/oby.2009.508. Epub 2010 Jan 28. Obesity (Silver Spring). 2010. PMID: 20111023 Free PMC article.
-
Interactive decision support for esophageal adenocarcinoma screening and surveillance.BMC Gastroenterol. 2019 Jun 27;19(1):109. doi: 10.1186/s12876-019-1022-0. BMC Gastroenterol. 2019. PMID: 31248371 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical